摘要
目的探讨ER、PR和HER2免疫组化检测在乳腺癌穿刺活检中的应用价值。方法选取我院2017年11月至2018年4月收治的50例乳腺癌患者作为研究对象,均进行术前穿刺活检HER2、ER、PR免疫组化检测和术中切除标本检测,比较术中切除标本和免疫组化检测的结果。结果术前穿刺活检HER2、ER、PR免疫组化检测和术中切除标本的阳性率比较无统计学差异(P>0.05);术前穿刺活检HER2、ER、PR免疫组化检测和术中切除标本的组织学一致性:ER为96.00%,PR为88.00%,HER2为80.00%。结论乳腺癌穿刺活检HER2、ER、PR免疫组化检测和术中切除标本一致性较高,可避免手术切除组织检测给患者带来的伤害,值得临床推广。
Objective To explore the application value of ER, PR and HER2 immunohistochemical test in breast cancerbiopsy. Methods A total of 50 patients with breast cancer admitted in our hospital from November 2017 to April 2018 wereselected as study subjects, all patients performed HER2, ER, PR immunohistochemical test in the preoperative biopsy andsurgical resection samples. The results of immunohistochemical test in the surgical resection samples and preoperativebiopsy were compared. Results There were no significant differences between the positive rates of HER2, ER, PRimmunohistochemiscal test in preoperative biopsy and the surgical resection samples（P〉0.05）. The histologic consistencybetween HER2, ER, PR immunohistochemiscal test in preoperative biopsy and the surgical resection samples of ER was96.00%, of PR was 88.00%, and of HER2 was 80.00%. Conclusion The HER2, ER, PR immunohistochemical test ofbreast cancer biopsy has a high consistency with the surgical resection samples, it can avoid the injury caused by tissuedetection, which is worth popularizing in clinic.
作者
苏群学
李峰
SU Qun-xue;LI Feng(Pathology Department,the Second People＇s Hospital of Kunshan,Kunshan 215300;Pathology Department,the Second Affiliated Hospital of Soochow University,Suzhou 215000,China)
出处
《临床医学研究与实践》
2018年第32期153-154,共2页
Clinical Research and Practice
关键词
乳腺癌
免疫组化
穿刺活检
breast cancer
immunohistochemistry
biopsy
